DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a medical device company focused on infectious disease and dermatology, today announced that it had satisfied the conditions necessary for triggering a $1,000,000 milestone payment under its supply and distribution agreement with Dr. Reddy’s Laboratories, Inc. (“DRL”) for the commercialization of EpiCeram® (the “DRL Agreement”). The milestone payment is for a non-sales milestone previously described in the Company’s public filings as Specified Event 2. This represents the second milestone payment received by the Company under the DRL Agreement.
